Physician profile
Ruth E Lamar
NPI 1578597704
$6,230.93
in general payments reported to CMS, 2019-2025
55 companies · $29.06 in 2025
The $29.06 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,813 · 2020: $292 · 2021: $363 · 2022: $167 · 2023: $1,456 · 2024: $1,111 · 2025: $29.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,543 · Education: $53.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.30 |
| Education | $53.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $542.74 | 2019-2024 | Darzalex, Imbruvica, Rybrevant |
| Merck Sharp & Dohme LLC | $523.09 | 2019-2024 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $494.66 | 2019-2024 | Reblozyl, Opdivo, Augtyro |
| Astrazeneca Pharmaceuticals Lp | $437.30 | 2019-2024 | Enhertu, Lynparza, Calquence |
| Genentech USA, INC. | $377.14 | 2019-2024 | Polivy, Tecentriq |
| Novartis Pharmaceuticals Corporation | $364.28 | 2019-2024 | |
| Amgen INC. | $323.37 | 2019-2023 | Kyprolis |
| Seagen INC. | $274.92 | 2019-2023 | Adcetris, Tukysa |
| Lilly USA, LLC | $197.40 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $170.76 | 2019-2024 | Reblozyl, Opdualag |
| Pfizer INC. | $169.48 | 2019-2024 | |
| Incyte Corporation | $146.48 | 2019-2024 | Monjuvi, Pemazyre, Jakafi |
| Gilead Sciences, INC. | $144.68 | 2019-2024 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $135.01 | 2023-2024 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $129.25 | 2020-2024 | Libtayo |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Lamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.